Lupus & antiphospholipid syndrome
Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study
Authors' conclusion
CD180-anchored, stage-resolved profiling indicates that clinical quiescence may not fully equate to immunological normalisation in SLE.
Study context
- Population
- Patients with SLE (active or inactive/low-activity) and healthy controls (HCs); peripheral CD19+ B cells
- Participants
- 27 / 29 / 14
- Exposure
- Active SLE and inactive/low-activity SLE vs healthy controls
- HCsn = 27reference
- Active SLEn = 29
- Inactive/low-activity SLEn = 14
- Outcome
- Distribution of CD180- plasmablast-lineage stages (subsets 2-5) along the CD180-loss trajectory
Methodological detailsflow cytometry, Benjamini-Hochberg false discovery rate (FDR) adjustment
- Flow cytometry
- Benjamini-Hochberg FDR adjustment
Main finding
As reported in the abstract
CD180- plasmablast-lineage stages (subsets 2-5)
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| CXCR5 positivity at subset 0Active SLE vs HCs · reduced | FDR-adjusted p=0.0273 |
| CXCR5 positivity at subset 0Inactive/low-activity SLE vs HCs · reduced | FDR-adjusted p=0.0015 |
| CXCR5 positivity at subset 3Active SLE vs HCs · reduced | FDR-adjusted p=0.0273 |
CD11c and B-cell maturation antigen (BCMA) expression
- CD11c enriched in upstream compartments during active disease
- BCMA increased in mature downstream CD180- stages
Original publication
Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study. Lupus Sci Med. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →